Metabolic acetate therapy for the treatment of traumatic brain injury
- PMID: 19803785
- PMCID: PMC2824219
- DOI: 10.1089/neu.2009.0994
Metabolic acetate therapy for the treatment of traumatic brain injury
Abstract
Patients suffering from traumatic brain injury (TBI) have decreased markers of energy metabolism, including N-acetylaspartate (NAA) and ATP. In the nervous system, NAA-derived acetate provides acetyl-CoA required for myelin lipid synthesis. Acetate can also be oxidized in mitochondria for the derivation of metabolic energy. In the current study, using the controlled cortical impact model of TBI in rats, we investigated the effects of the hydrophobic acetate precursor, glyceryltriacetate (GTA), as a method of delivering metabolizable acetate to the injured brain. We found that GTA administration significantly increased the levels of both NAA and ATP in the injured hemisphere 4 and 6 days after injury, and also resulted in significantly improved motor performance in rats 3 days after injury.
Figures
References
-
- Arun P. Madhavarao C.N. Moffett J.R. Namboodiri A.M. Antipsychotic drugs increase N-acetylaspartate and N-acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells. J. Neurochem. 2008;106:1669–1680. - PubMed
-
- Bailey J.W. Haymond M.W. Miles J.M. Triacetin: A potential parenteral nutrient. JPEN J. Parenter. Enteral Nutr. 1991;15:32–36. - PubMed
-
- Clark J.B. N-acetylaspartate: A marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 1998;20:271–276. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
